Specific lipid lowering therapy in the management of diabetes.
作者信息
Durrington P N
机构信息
University of Manchester Department of Medicine, Manchester Royal Infirmary, UK.
出版信息
Postgrad Med J. 1991 Oct;67(792):947-52. doi: 10.1136/pgmj.67.792.947.
Abstract
摘要
相似文献
1
Specific lipid lowering therapy in the management of diabetes.糖尿病管理中的特定降脂治疗
Postgrad Med J. 1991 Oct;67(792):947-52. doi: 10.1136/pgmj.67.792.947.
2
Clinical trial assessment of lipid-acting drugs in diabetic patients.糖尿病患者中脂质作用药物的临床试验评估。
Am J Cardiol. 1998 Apr 23;81(8A):58F-59F. doi: 10.1016/s0002-9149(98)00265-3.
3
Outcomes of lipid-lowering treatment in postmenopausal women.绝经后女性降脂治疗的结果
Drugs Aging. 2002;19(8):595-604. doi: 10.2165/00002512-200219080-00005.
4
[Guideline for management of lipid metabolism].[脂质代谢管理指南]
Nihon Rinsho. 2002 Sep;60 Suppl 9:675-8.
5
Recent trials of lipid lowering.近期降脂试验
Int J Clin Pract. 2007 Jul;61(7):1145-59. doi: 10.1111/j.1742-1241.2007.01425.x.
6
Plasma lipids-lipoproteins in coronary artery disease. Regulation and control.冠状动脉疾病中的血浆脂质-脂蛋白。调节与控制。
Chest. 1980 Nov;78(5):679-81. doi: 10.1378/chest.78.5.679.
7
Secondary prevention of coronary disease with lipid-lowering drugs.
Lancet. 1989 Mar 4;1(8636):473-4.
8
[Evaluation of the effectiveness of hypolipidemic preparations in coronary arteriosclerosis].[降血脂制剂对冠状动脉粥样硬化的疗效评估]
Kardiologiia. 1984 Sep;24(9):54-7.
9
[Lipid factors and evolution of the atherosclerotic plaque: review of recent trials].
G Ital Cardiol. 1996 Dec;26(12):1481-93.
10
Management of dyslipidemia in adults with diabetes.成人糖尿病患者血脂异常的管理。
Diabetes Care. 2003 Jan;26 Suppl 1:S83-6. doi: 10.2337/diacare.26.2007.s83.
本文引用的文献
1
Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration.糖尿病患者的血清高密度脂蛋白胆固醇：影响其浓度的因素分析。
Clin Chim Acta. 1980 May 21;104(1):11-23. doi: 10.1016/0009-8981(80)90130-8.
2
The effect of continuous subcutaneous insulin infusion on very-low-density lipoprotein triglyceride metabolism in type I diabetes mellitus.
Diabetes. 1983 Jan;32(1):75-81. doi: 10.2337/diab.32.1.75.
3
The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study.在世卫组织多国研究的九个糖尿病患者群体样本中，循环葡萄糖和甘油三酯浓度及其与其他“风险因素”的相互作用作为动脉疾病决定因素的作用。
Diabetes Care. 1983 Jul-Aug;6(4):361-9. doi: 10.2337/diacare.6.4.361.
4
Diabetes mellitus death-rates in England and Wales 1920-70 and food supplies.1920年至1970年英格兰和威尔士的糖尿病死亡率与食物供应情况
Lancet. 1974 Oct 26;2(7887):998-1002. doi: 10.1016/s0140-6736(74)92085-6.
5
Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia.普罗布考治疗杂合子家族性高胆固醇血症的双盲、安慰剂对照、交叉试验。
Atherosclerosis. 1985 May;55(2):187-94. doi: 10.1016/0021-9150(85)90097-8.
6
Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.洛伐他汀用于降低非胰岛素依赖型糖尿病患者的胆固醇水平。
N Engl J Med. 1988 Jan 14;318(2):81-6. doi: 10.1056/NEJM198801143180204.
7
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.赫尔辛基心脏研究：吉非贝齐用于中年血脂异常男性的一级预防试验。治疗安全性、危险因素变化及冠心病发病率
N Engl J Med. 1987 Nov 12;317(20):1237-45. doi: 10.1056/NEJM198711123172001.
8
Evidence that lowering serum lipids favourably influences coronary heart disease.降低血脂对冠心病有积极影响的证据。
Q J Med. 1987 Feb;62(238):87-95.
9
Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.
Acta Med Scand. 1988;223(5):405-18. doi: 10.1111/j.0954-6820.1988.tb15891.x.
10
Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus.ω-3脂肪酸在非胰岛素依赖型糖尿病中的不良代谢作用。
Ann Intern Med. 1988 May;108(5):663-8. doi: 10.7326/0003-4819-108-5-663.
Zotero 插件